Form 4: Ligand Pharmaceuticals CFO Octavio Espinoza Reports Stock Sale and Option Grant

Octavio Espinoza, CFO of Ligand Pharmaceuticals, reported selling 5,000 shares of common stock and receiving a grant of 32,717 employee stock options.

Summary

• On March 4, 2025, Octavio Espinoza, the Chief Financial Officer of Ligand Pharmaceuticals, reported transactions involving the company's stock.
• Espinoza sold 5,000 shares of common stock at a weighted average price of $115.0297 per share.
• He also acquired 7,484 restricted stock units (RSUs), each representing a contingent right to receive one share of Ligand's common stock, vesting in three equal annual installments starting February 15, 2026.
• Additionally, Espinoza received an employee stock option grant for 32,717 shares with an exercise price of $115.26, vesting incrementally over time starting six months after the grant date.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of insider transactions, with no inherent positive or negative sentiment.

Future Outlook

The RSUs vest over three years, and the stock options vest over time, indicating continued service and alignment with the company's long-term performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives.

Comparison to Industry Standards

• Stock option grants and RSU awards are common forms of executive compensation in the pharmaceutical industry, aligning management incentives with shareholder value.
• Vesting schedules for RSUs and stock options are typically structured to encourage long-term commitment from executives.
• The specific terms of Espinoza's grants (vesting schedule, exercise price) would need to be compared to those of executives at peer companies to assess their competitiveness.

Stakeholder Impact

• Shareholders are informed about the CFO's transactions in company stock, providing transparency.
• The vesting schedules of the RSUs and stock options may incentivize the CFO to focus on long-term company performance.

Key Dates